Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption

Advanced Drug Delivery Reviews

Volumn 60, Issue 6, 2008, Pages 717-733

  Custodio, Joseph M ^a   Wu, Chi Yuan ^a   Benet, Leslie Z ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Absorption; BCS; BDDCS; Disposition; Elimination; Food effects; Interplay; Transporter

Indexed keywords

ABSORPTION; ENZYME ACTIVITY; FOOD PRODUCTS; METABOLISM; MOLECULAR STRUCTURE;

DRUG AVAILABILITY; FOOD EFFECTS;

DRUG DELIVERY;

ABACAVIR; ACICLOVIR; AMILORIDE; AMITRIPTYLINE; ATROPINE; BUSPIRONE; CAFFEINE; CAPTOPRIL; CHLOROQUINE; CHLORPHENIRAMINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOCHROME P450 3A4; DESIPRAMINE; DIAZEPAM; DILTIAZEM; DIPHENHYDRAMINE; DISOPYRAMIDE; DOXEPIN; DOXYCYCLINE; ENALAPRIL; ERGOMETRINE; FELODIPINE; FEXOFENADINE; GLYCEROL OLEATE; INDINAVIR; LAPATINIB; PARACETAMOL; PHENAZONE; UNINDEXED DRUG;

APPLE JUICE; BIOEQUIVALENCE; CELL STRAIN; CELL STRAIN CACO 2; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG DISPOSITION; DRUG ELIMINATION; DRUG FORMULATION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; FOOD AND DRUG ADMINISTRATION; FOOD DRUG INTERACTION; GARLIC; GRAPEFRUIT JUICE; HYPERICUM PERFORATUM; INTESTINE TRANSIT TIME; LIPID DIET; MONOLAYER CULTURE; NONHUMAN; ORANGE JUICE; PHYSICAL CHEMISTRY; POSTPRANDIAL STATE; PREDICTION; PRIORITY JOURNAL; RED WINE; REVIEW; STOMACH SECRETION;

ADMINISTRATION, ORAL; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DIETARY FATS; FOOD-DRUG INTERACTIONS; FORECASTING; GASTROINTESTINAL TRACT; HUMANS; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY;

EID: 39149115065     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2007.08.043     Document Type: Review

References (126)

1. Singh B.N. Effects of food on clinical pharmacokinetics. Clin. Pharmacokinet. 37 (1999) 213-255
2. Harris R.Z., Jang G.R., and Tsunoda S. Dietary effects on drug metabolism and transport. Clin. Pharmacokinet. 42 (2003) 1071-1088
3. Food and Drug Administration. Guidance for Industry: Food-Effect Bioavailability and Fed Bioequivalence Studies (2002), Food and Drug Administration, Rockville, MD. http://www.fda.gov/cder/guidance/index.htm Available at http://www.fda.gov/cder/guidance/index.htm
4. Jones H.M., Parrott N., Ohlenbusch G., and Lavé T. Predicting pharmacokinetic food effects using biorelevant solubility media and physiologically based modeling. Clin. Pharmacokinet. 45 (2006) 1213-1226
5. Lentz K.A., Quitko M., Morgan D.G., Grace J.E., Gleason C., and Marathe P.H. Development and validation of a preclinical food effect model. J. Pharm. Sci. 96 (2007) 459-472
6. Wei H., and Löbenberg R. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur. J. Pharm. Sci. 29 (2006) 45-52
7. Kataoka M., Masaoka Y., Sakuma S., and Yamashita S. Effect of food intake on the oral absorption of poorly water-soluble drugs: in vitro assessment of drug dissolution and permeation assay system. J. Pharm. Sci. 95 (2006) 2051-2061
8. Amidon G.L., Lennernas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
9. Food and Drug Administration. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System (2000), Food and Drug Administration, Rockville, MD. http://www.fda.gov/cder/guidance/index.htm Retrieved from www.fda.gov/cder/guidance/index.htm
10. Wu C.-Y., and Benet L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm. Res. 22 (2005) 11-23
11. Lennernas H. Human jejunal effective permeability and its correlation with preclinical drug absorption models. J. Pharm. Pharmacol. 49 (1997) 627-638
12. van de Waterbeemd H. The fundamental variables of the biopharmaceutics classification system (BCS): a commentary. Eur. J. Pharm. Sci. 7 (1998) 1-3
13. Blume H.H., and Schug B.S. The biopharmaceutics classification system (BCS): class III drugs-better candidates for BA/BE waiver?. Eur. J. Pharm. Sci. 9 (1999) 117-121
14. Fleisher D., Li C., Zhou Y., Pao L.H., and Karim A. Drug, meal and formulation interactions influencing drug absorption after oral administration, clinical implications. Clin. Pharmacokinet. 36 (1999) 233-254
15. Löbenberg R., and Amidon G.L. Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur. J. Pharm. Biopharm. 50 (2000) 3-12
16. Avdeef A. Physicochemical profiling (solubility, permeability and charge state). Curr. Top. Med. Chem. 1 (2001) 277-351
17. Rege B.D., Yu L.X., Hussain A.S., and Polli J.E. Effect of common excipients on Caco-2 transport of low-permeability drugs. J. Pharm. Sci. 90 (2001) 1776-1786
18. Tannergren C., Langguth P., and Hoffmann K.J. Compound mixtures in Caco-2 cell permeability screens as a means to increase screening capacity. Pharmazie 56 (2001) 337-342
19. Kanfer I. Report on the International Workshop on the Biopharmaceutics Classification System (BCS): scientific and regulatory aspects in practice. J. Pharm. Pharm. Sci. 5 (2002) 1-4
20. Lennernas H., Knutson L., Knutson T., Hussain A., Lesko L., Salmonson T., and Amidon G.L. The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique. Eur. J. Pharm. Sci. 15 (2002) 271-277
21. Martinez M.N., and Amidon G.L. A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J. Clin. Pharmacol. 42 (2002) 620-643
22. Taub M.E., Kristensen L., and Frokjaer S. Optimized conditions for MDCK permeability and turbidimetric solubility studies using compounds representative of BCS classes I-IV. Eur. J. Pharm. Sci. 15 (2002) 331-340
23. Yu L.X., Amidon G.L., Polli J.E., Zhao H., Mehta M.U., Conner D.P., Shah V.P., Lesko L.J., Chen M.L., Lee V.H., and Hussain A.S. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 19 (2002) 921-925
24. Bergström C.A., Strafford M., Lazorova L., Avdeef A., Luthman K., and Artursson P. Absorption classification of oral drugs based on molecular surface properties. J. Med. Chem. 46 (2003) 558-570
25. Tannergren C., Knutson T., Knutson L., and Lennernas H. The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. Br. J. Clin. Pharmacol. 55 (2003) 182-190
26. Lindenberg M., Kopp S., and Dressman J.B. Classification of orally administered drugs on the World Health Organization Model of Essential Medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm. 58 (2004) 265-278
27. Jorgensen W.L., and Duffy E.M. Prediction of drug solubility from structure. Adv. Drug Deliv. Rev. 54 (2002) 355-366
28. Bergström C.A. In silico predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption. Basic Clin. Pharmacol. Toxicol. 96 (2005) 156-161
29. Bergström C.A. Computational models to predict aqueous drug solubility, permeability and intestinal absorption. Expert Opin. Drug Metab. Toxicol. 1 (2005) 613-627
30. Amidon G.L., Sinko P.J., and Fleisher D. Estimating human oral fraction dose absorbed: a correlation using rat intestinal membrane permeability for passive and carrier-mediated compounds. Pharm. Res. 5 (1988) 651-654
31. Kunta J.R., and Sinko P.J. Intestinal drug transporters: in vivo function and clinical importance. Curr. Drug Met. 5 (2004) 109-124
32. Fagerholm U. Prediction of human pharmacokinetics - gastrointestinal absorption. J. Pharm. Pharmacol. 59 (2007) 905-916
33. Paine M.F., Shen D.D., Kunze K.L., Perkins J.D., Marsh C.L., McVicar J.P., Barr D.M., Gillies B.S., and Thummel K.E. First-pass metabolism of midazolam by the human intestine. Clin. Pharmacol. Ther. 60 (1996) 14-24
34. DeSesso J.M., and Jacobson C.F. Anatomical and physiological parameters affecting gastrointestinal absorption in humans and rats. Food Chem. Toxicol. 39 (2001) 209-228
35. Shitara Y., Horie T., and Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur. J. Pharm. Sci. 27 (2006) 425-446
36. Kim R.B. Transporters and drug discovery: why, when, and how. Mol. Pharm. 3 (2005) 26-32
37. Seithel A., Karlsson J., Hilgendorf C., Björquist A., and Ungell A.L. Variability in mRNA expression of ABC- and SLC-transporters in human intestinal cells: comparison between human segments and Caco-2 cells. Eur. J. Pharm. Sci. 28 (2006) 291-299
38. Englund G., Rorsman F., Rönnblom A., Karlbom U., Lazorova L., Gråsjö J., Kindmark A., and Artursson P. Regional levels of drug transporters along the human intestinal tract: co-expression of ABC and SLC transporters and comparison with Caco-2 cells. Eur. J. Pharm. Sci. 29 (2006) 269-277
39. Kalantzi L., Goumas K., Kalioras V., Abrahamsson B., Dressman J.B., and Reppas C. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm. Res. 23 (2006) 165-176
40. Brouwers J., Tack J., Lammert F., and Augustijns P. Parallel monitoring of plasma and intraluminal drug concentrations in man after oral administration of fosamprenavir in the fasted and fed state. Pharm. Res. 24 (2007) 1862-1869
41. Welling P.G. Effects of food on drug absorption. Annu. Rev. Nutr. 16 (1996) 383-415
42. Galia E., Nicolaides E., Hörter D., Löbenberg R., Reppas C., and Dressman J.B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 15 (1998) 698-705
43. Dressman J.B., and Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 11 (2000) S73-S80
44. Leyden J.J. Absorption of minocycline hydrochloride and tetracycline hydrochloride, effect of food, milk, and iron. J. Am. Acad. Dermatol. 12 (1985) 308-312
45. Carver P.L., Fleisher D., Zhou S.Y., Kaul D., Kazanjian P., and Li C. Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. Pharm. Res. 16 (1999) 718-724
46. Liedholm H., and Melander A. Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation. Clin. Pharmacol. Ther. 40 (1986) 29-36
47. Ratain M.J., and Cohen E.E. The value meal: how to save $1,700 per month or more on lapatinib. J. Clin. Oncol. 25 (2007) 3397-3398
48. Schmidt L.E., and Dalhoff K. Food-drug interactions. Drugs. 62 (2002) 1481-1502
49. Smith D.A. Design of drugs through a consideration of drug metabolism and pharmacokinetics. Eur. J. Drug Metab. Pharmacokinet. 3 (1994) 193-199
50. Ito K., Suzuki H., Horie T., and Sugiyama Y. Apical/basolateral surface expression of drug transporters and its role in vectorial drug transport. Pharm. Res. 22 (2005) 1559-1577
51. Kim R.B., Fromm M.F., Wandel C., Leake B., Wood A.J., Roden D.M., and Wilkinson G.R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 101 (1998) 289-294
52. Polli J.W., Wring S.A., Humphreys J.E., Huang L., Morgan J.B., Webster L.O., and Serabjit-Singh C.S. Rational use of in vitro P-glycoprotein assays in drug discovery. J. Pharmacol. Exp. Ther. 299 (2001) 620-628
53. Taub M.E., Kristensen L., and Frokjaer S. Optimized conditions for MDCK permeability and turbidimetric solubility studies using compounds representative of BCS classes I-IV. Eur. J. Pharm. Sci. 15 (2002) 331-340
54. Lu S., Gough A.W., Bobrowski W.F., and Stewart B.H. Transport properties are not altered across Caco-2 cells with heightened TEER despite underlying physiological and ultrastructural changes. J. Pharm. Sci. 85 (1996) 270-273
55. Yee S. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man-fact or myth. Pharm. Res. 14 (1997) 763-766
56. Watanabe K., Sawano T., Terada K., Endo T., Sakata M., and Sato J. Studies on intestinal absorption of sulpiride (1): carrier-mediated uptake of sulpiride in the human intestinal cell line Caco-2. Biol. Pharm. Bull. 25 (2002) 885-890
57. Watanabe K., Sawano T., Endo T., Sakata M., and Sato J. Studies on intestinal absorption of sulpiride (2): transepithelial transport of sulpiride across the human intestinal cell line Caco-2. Biol. Pharm. Bull. 25 (2002) 1345-1350
58. Sun D., Lennernas H., Welage L.S., Barnett J.L., Landowski C.P., Foster D., Fleisher D., Lee K.D., and Amidon G.L. Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm. Res. 19 (2002) 1400-1416
59. Bourdet D.L., Pollack G.M., and Thakker D.R. Intestinal absorptive transport of the hydrophilic cation ranitidine: a kinetic modeling approach to elucidate the role of uptake and efflux transporters and paracellular vs. transcellular transport in Caco-2 cells. Pharm. Res. 23 (2006) 1178-1187
60. Hilgendorf C., Ahlin G., Seithel A., Artursson P., Ungell A.L., and Karlsson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos. 35 (2007) 1333-1340
61. Balakrishnan A., Sussman D.J., and Polli J.E. Development of stably transfected monolayer overexpressing the human apical sodium-dependent bile acid transporter (hASBT). Pharm. Res. 22 (2005) 1269-1280
62. Balakrishnan A., and Polli J.E. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol. Pharm. 3 (2006) 223-230
63. Balimane P.V., Chong S., Patel K., Quan Y., Timoszyk J., Han Y.H., Wang B., Vig B., and Faria T.N. Peptide transporter substrate identification during permeability screening in drug discovery: comparison of transfected MDCK-hPepT1 cells to Caco-2 cells. Arch. Pharm. Res. 30 (2007) 507-518
64. Satoh H., Yamashita F., Tsujimoto M., Murakami H., Koyabu N., Ohtani H., and Sawada Y. Citrus juices inhibit the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos. 33 (2005) 518-523
65. Matsushima S., Maeda K., Kondo C., Hirano M., Sasaki M., Suzuki H., and Sugiyama Y. Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J. Pharmacol. Exp. Ther. 314 (2005) 1059-1067
66. Sasaki M., Suzuki H., Ito K., Abe T., and Sugiyama Y. Transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II cell monolayer expressing both human organic anion-transporting polypeptide (OATP2/SLC21A6) and multidrug resistance-associated protein 2 (MRP2/ABCC2). J. Biol. Chem. 277 (2002) 6497-6503
67. Letschert K., Komatsu M., Hummel-Eisenbeiss J., and Keppler D. Vectorial transport of the peptide CCK-8 by double-transfected MDCKII cells stably expressing the organic anion transporter OATP1B3 (OATP8) and the export pump ABCC2. J. Pharmacol. Exp. Ther. 313 (2005) 549-556
68. Mita S., Suzuki H., Akita H., Hayashi H., Onuki R., Hofmann A.F., and Sugiyama Y. Inhibition of bile acid transport across Na+/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs. Drug Metab. Dispos. 34 (2006) 1575-1581
69. Tolle-Sander S., Rautio J., Wring S., Polli J.W., and Polli J.E. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm. Res. 20 (2003) 757-764
70. Cummins C.L., Jacobsen W., and Benet L.Z. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J. Pharmacol. Exp. Ther. 300 (2002) 1036-1045
71. Cummins C.L., Salphati L., Reid M.J., and Benet L.Z. In vivo modulation of intestinal CYP3A metabolism by P-glycoprotein: studies using the rat single-pass intestinal perfusion model. J. Pharmacol. Exp. Ther. 305 (2003) 306-314
72. Cummins C.L., Jacobsen W., Christians U., and Benet L.Z. CYP3A4-transfected Caco-2 cells as a tool for understanding biochemical absorption barriers: studies with sirolimus and midazolam. J. Pharmacol. Exp. Ther. 308 (2004) 143-155
73. Chang J.H., and Benet L.Z. Glucuronidation and the transport of the glucuronide metabolites in LLC-PK1 cells. Mol. Pharm. 2 (2005) 428-434
74. Lau Y.Y., Huang Y., Frassetto L., and Benet L.Z. Effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers. Clin. Pharmacol. Ther. 81 (2007) 194-204
75. Gupta S.K., and Benet L.Z. Effect of food on the pharmacokinetics of cyclosporine in healthy subjects following oral and intravenous administration. J. Clin. Pharmacol. 30 (1990) 643-653
76. Physicians' Desk Reference. 61st ed. (2007), Thomson PDR, Montvale, NJ 2149-2153
77. Klein S., Butler J., Hempenstall J.M., Reppas C., and Dressman J.B. Media to simulate the postprandial stomach I. Matching the physiochemical characteristics of standard breakfasts. J. Pharm. Pharmacol. 56 (2004) 605-610
78. Lui C.Y., Amidon G.L., Berardi R.R., Fleisher D., Youngberg C., and Dressman J.B. Comparison of gastrointestinal pH in dogs and humans: implications on the use of the beagle dog as a model for oral absorption in humans. J. Pharm. Sci. 75 (1986) 271-274
79. Charman W.N., Porter C.J.H., Mithani S., and Dressman J.B. Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. J. Pharm. Sci. 86 (1997) 269-282
80. Tso P. Intestinal lipid absorption. In: Johnson R. (Ed). Physiology of the Gastrointestinal Tract (1994), Raven Press, New York 1867-1907
81. Konishi T., Satsu H., Hatsugai Y., Aizawa K., Inakuma T., Nagata S., Sakuda S.H., Nagasawa H., and Shimizu M. Inhibitory effect of a bitter melon extract on the P-glycoprotein activity in intestinal Caco-2 cells. Br. J. Pharmacol. 143 (2004) 379-387
82. Konishi T., Satsu H., Hatsugai Y., Aizawa K., Inakuma T., Nagata S., Sakuda S.H., Nagasawa H., and Shimizu M. A bitter melon extract inhibits the P-glycoprotein activity in intestinal Caco-2 cells: monoglyceride as an active compound. Biofactors 22 (2004) 71-74
83. Ingels F., Deferme S., Destexhe E., Oth M., Van den Mooter G., and Augustijns P. Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. Int. J. Pharm. 232 (2002) 183-192
84. Balakrishnan A., and Polli J.E. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target. Mol. Pharm. 3 (2006) 223-230
85. Benet L.Z., Cummins C.L., and Wu C.Y. Unmasking the dynamic interplay between efflux transporters and metabolic enzymes. Int. J. Pharm. 277 (2004) 3-9
86. Benet L.Z., Cummins C.L., and Wu C.Y. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr. Drug Metab. 4 (2003) 393-398
87. Dresser G.K., Bailey D.G., Leake B.F., Schwarz U.I., Dawson P.A., Freeman D.J., and Kim R.B. Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. Clin. Pharmacol. Ther. 71 (2002) 11-20
88. Lavelle J., Follansbee S., Trapnell C.B., Buhles W.C., Griffy K.G., Jung D., Dorr A., and Connor J. Effect of food on the relative bioavailability of oral ganciclovir. J. Clin. Pharmacol. 36 (1996) 238-241
89. Singh B.N. A quantitative approach to probe the dependence and correlation of food-effect with aqueous solubility, dose/solubility ratio, and partition coefficient (Log P) for orally active drugs administered as immediate-release formulations. Drug Dev. Res. 65 (2005) 55-75
90. Gu C.H., Li H., Levons J., Lentz K., Gandhi R.B., Raghavan K., and Smith R.L. Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm. Res. 24 (2007) 1118-1130
91. Lipinski C.A. Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods. 44 (2000) 235-249
92. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 46 (2001) 3-26
93. Azarmi S., Roa W., and Löbenberg R. Current perspectives in dissolution testing of conventional and novel dosage forms. Int. J. Pharm. 28 (2007) 12-21
94. Al-Behaisi S., Antal I., Morovján G., Szúnyog J., Drabant S., Marton S., and Klebovich I. In vitro simulation of food effect on dissolution of deramciclane film-coated tablets and correlation with in vivo data in healthy volunteers. Eur. J. Pharm. Sci. 15 (2002) 157-162
95. Bailey D.G., Spence J.D., Edgar B., Bayliff C.D., and Arnold J.M. Ethanol enhances the hemodynamic effects of felodipine. Clin. Invest. Med. 12 (1989) 357-362
96. Dresser G.K., and Bailey D.G. The effects of fruit juices on drug disposition: a new model for drug interactions. Eur. J. Clin. Invest. 33 (2003) 10-16
97. Dresser G.K., Kim R.B., and Bailey D.G. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin. Pharmacol. Ther. 77 (2005) 170-177
98. Petri N., Tannergren C., Rungstad D., and Lennernas H. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharm. Res. 21 (2004) 1398-1404
99. Kamath A.V., Yao M., Zhang Y., and Chong S. Effect of fruit juices on the oral bioavailability of fexofenadine in rats. J. Pharm. Sci. 94 (2005) 233-239
100. Parker R.B., Yates C.R., Soberman J.E., and Laizure S.C. Effects of grapefruit juice on intestinal P-glycoprotein evaluation using digoxin in humans. Pharmacotherapy 23 (2003) 979-987
101. Schwarz U.I., Seemann D., Oertel R., Miehlke S., Kuhlish E., Fromm M.F., Kim R.B., Bailey D.G., and Kirch W. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin. Pharmacol. Ther. 77 (2005) 291-301
102. Anuchapreeda S., Leechanachai P., Smith M.M., Ambudkar S.V., and Limtrakul P. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem. Pharmacol. 64 (2002) 573-582
103. Zhang S., and Morris M.E. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J. Pharmacol. Exp. Ther. 304 (2003) 1258-1267
104. Kitagawa S., Nabekura T., and Kamiyama S. Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J. Pharm. Pharmacol. 56 (2004) 1001-1005
105. Barthomeuf C., Grassi J., Demeule M., Fournier C., Boivin D., and Béliveau R. Inhibition of P-glycoprotein transport function and reversion of MDR1 multidrug resistance by cnidiadin. Cancer Chemother. Pharmacol. 56 (2005) 173-181
106. Kitagawa S., Nabekura T., Kamiyama S., Takahashi T., Nakamura Y., Kashiwada Y., and Ikeshiro Y. Effects of alkyl gallates on P-glycoprotein function. Biochem. Pharmacol. 70 (2005) 1262-1266
107. Fuchikami H., Satoh H., Tsujimoto M., Ohdo S., Ohtani H., and Sawada Y. Effects of herbal extracts on the function of human organic anion-transporting polypeptide OATP-B. Drug Metab. Dispos. 34 (2006) 577-582
108. Tseng E., Kamath A., and Morris M.E. Effect of organic isothiocyanates on the P-glycoprotein- and MRP1-mediated transport of daunomycin and vinblastine. Pharm. Res. (2002) 1509-1515
109. Wu C.-P., Calcagno A.M., Hladky S.B., Ambudkar S.V., and Barrand M.A. Modulatory effects of plant phenols on human multidrug resistance proteins 1, 4, and 5 (ABCC1, 4 and 5). FEBS J. 272 (2005) 4725-4740
110. Brocks D.R., and Wasan K.M. The influence of lipids on stereoselective pharmacokinetics of halofantrine: important implications in food-effect studies involving drugs that bind to lipoproteins. J. Pharm. Sci. 91 (2002) 1817-1826
111. Humberstone A.J., Porter C.J., Edwards G.A., and Charman W.N. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. J. Pharm. Sci. 87 (1998) 936-942
112. Persson E.M., Nilsson R.G., Hansson G.I., Löfgren L.J., Libäck F., Knutson L., Abrahamsson B., and Lennernäs H. A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine. Pharm. Res. 23 (2006) 742-751
113. Humberstone A.J., and Charman W.N. Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv. Drug Deliv. Rev. 25 (1997) 103-128
114. Gershkovich P., Shtainer D., and Hoffman A. The effect of a high-fat meal on the pharmacodynamics of a model lipophilic compound that binds extensively to triglyceride-rich lipoproteins. Int. J. Pharm. 333 (2007) 1-4
115. Gershkovich P., and Hoffman A. Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. Eur. J. Pharm. Sci. 32 (2007) 24-32
116. Porter C.J., Trevaskis N.L., and Charman W.N. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat. Rev. Drug Discov. 6 (2007) 231-248
117. Mueller E.A., Kovarik J.M., van Bree J.B., Grevel J., Lücker P.W., and Kutz K. Influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine in a crossover comparison with the market formulation. Pharm. Res. 11 (1994) 151-155
118. Mueller E.A., Kovarik J.M., and Kutz K. Minor influence of a fat-rich meal on the pharmacokinetics of a new oral formulation of cyclosporine. Transplant. Proc. 26 (1994) 2957-2958
119. Kaukonen A.M., Boyd B.J., Charman W.N., and Porter C.J. Drug solubilization behavior during in vitro digestion of suspension formulations of poorly water-soluble drugs in triglyceride lipids. Pharm. Res. 21 (2004) 254-260
120. Carey M.C., Small D.M., and Bliss C.M. Lipid digestion and absorption. Annu. Rev. Physiol. 45 (1983) 651-677
121. Kossena G.A., Charman W.N., Boyd B.J., Dunstan D.E., and Porter C.J. Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach. J. Pharm. Sci. 93 (2004) 332-348
122. Kossena G.A., Charman W.N., Boyd B.J., and Porter C.J. Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug. J. Pharm. Sci. 94 (2005) 481-492
123. Subramanian R., and Wasan K.M. Effect of lipid excipients on in vitro pancreatic lipase activity. Drug Dev. Ind. Pharm. 29 (2003) 885-890
124. Risovic V., Sachs-Barrable K., Boyd M., and Wasan K.M. Potential mechanisms by which Peceol increases the gastrointestinal absorption of amphotericin B. Drug. Dev. Ind. Pharm. 30 (2004) 767-774
125. Wasan K.M., Sachs-Barrable K., and Lee S.D. Potential mechanisms by which lipid excipients increase the oral gastrointestinal absorption of drugs: a case study using amphotericin B. Bull. Tech. Gattefossé (2006) 31-42
126. Ingels F.M., and Augustijns P.F. Biological, pharmaceutical, and analytical considerations with respect to the transport media used in the absorption screening system, Caco-2. J. Pharm. Sci. 92 (2003) 1545-1558